Regarding its application for pathologies other than T2DM, as mentioned before, numerous studies have demonstrated CV benefits for almost all GLP-1 agonists [40,41] which is due to the wide expression distribution of its GLP-1R. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.